Study describes health outcomes following simultaneous vaccination with monovalent primary series COVID-19 vaccines

Brasil Notícia Notícia

Study describes health outcomes following simultaneous vaccination with monovalent primary series COVID-19 vaccines
Brasil Últimas Notícias,Brasil Manchetes
  • 📰 NewsMedical
  • ⏱ Reading Time:
  • 50 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 23%
  • Publisher: 71%

Study describes health outcomes following simultaneous vaccination with monovalent primary series COVID-19 vaccines CDCgov DeptPopMed vaccine vaccination COVID19 coronavirus covid health

By Pooja Toshniwal PahariaJun 19 2023Reviewed by Danielle Ellis, B.Sc. In a recent study in Vaccine, researchers described simultaneous vaccination with primary series severe acute respiratory syndrome coronavirus 2 vaccines. They assessed 23 pre-determined health outcomes following SV among individuals aged five years and above in the Vaccine Safety Datalink .

Previous observational studies and clinical trials underpin simultaneous vaccinations. However, a few studies have reported increased risks of adverse events among individuals receiving SV with non-SARS-CoV-2 vaccines, e.g.

SV was described as the receipt of any non-SARS-CoV-2 vaccine on the day of the first or second doses of the primary SARS-CoV-2 vaccines, following the Advisory Committee on Immunization Practices guidelines. The vaccines were administered at different anatomical sites and not combined in the same syringe. Simultaneously administered vaccines were grouped to form mutually exclusive groups; e.g., all types of influenza vaccines were grouped into the “All Influenza” group.

Related StoriesAdverse events were rare following simultaneous vaccination with SARS-CoV-2 vaccines, with only 56 outcomes reported after the first and second doses. The adverse event rates among SV recipients SV did not differ significantly from that among non-SV recipients .

Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação:

NewsMedical /  🏆 19. in UK

Brasil Últimas Notícias, Brasil Manchetes

Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.

Is Guillain-Barré syndrome induced by SARS-CoV-2 vaccination?Is Guillain-Barré syndrome induced by SARS-CoV-2 vaccination?Is Guillain-Barré syndrome induced by SARS-CoV-2 vaccination? Eurosurveillanc covid COVID19 SARSCoV2 vaccination guillainbarresyndrome guillainbarre
Consulte Mais informação »

Indians are flocking to study at British universitiesIndians are flocking to study at British universitiesIn recent years universities across Britain have experienced a surge in applications from India, Nigeria and beyond. What explains the rise?
Consulte Mais informação »

AI chatbots in dermatology: Promising, but proceed with caution, says new studyAI chatbots in dermatology: Promising, but proceed with caution, says new studyStudy finds AI chatbots in dermatology show promise in answering patient questions and simplifying medical jargon, but limitations in accuracy and knowledge highlight the need for cautious integration into clinical practice.
Consulte Mais informação »

Could mutated blood cells hold the key to lower Alzheimer's risk?Could mutated blood cells hold the key to lower Alzheimer's risk?Could mutated blood cells hold the key to lower Alzheimer's risk? NatureMedicine StanfordMed alzheimers AD disease bloodcells mutated research
Consulte Mais informação »

Current estimates of national, state-level, and county-level prevalence of US adults reporting a lifetime diagnosis of depressionCurrent estimates of national, state-level, and county-level prevalence of US adults reporting a lifetime diagnosis of depressionCurrent estimates of national, state-level, and county-level prevalence of US adults reporting a lifetime diagnosis of depression CDCgov ORISEconnect depression mentalhealth health diagnosis
Consulte Mais informação »



Render Time: 2025-02-28 12:14:23